News - Eisai, Fycompa

Filter

Current filters:

EisaiFycompa

Popular Filters

Eisai’s Fycompa debuts in France following reimbursement agreement

21-05-2014

Japanese pharma company Eisai has launched its Fycompa (perampanel), the first in an entirely new class…

EisaiFranceFycompaMarkets & MarketingNeurologicalPharmaceuticalPricing

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

12-05-2014

Japanese drug major Eisai has exercised its option to jointly develop and commercialize its clinical…

Biogen IdecEisaiFycompaGermanyItalyLicensingNeurologicalPharmaceuticalPricingRegulationZebinix

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Eisai’s epilepsy drug Fycompa to launch in USA

Eisai’s epilepsy drug Fycompa to launch in USA

02-01-2014

The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will…

EisaiFycompaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalUSA

Eisai's EMEA operation cleared as US supplier of Fycompa in USA

11-09-2013

The US Food and Drug Administration has approved the US supply of Japanese pharma major Eisai's (TYO:…

EisaiFycompaNeurologicalNorth AmericaPharmaceuticalProduction

Eisai launches legal action after "unreasonable" delay for its epilepsy drug

20-08-2013

Japanese drug major Eisai (TYO: 4523) has taken legal action in the USA over the delay of the recommendation…

EisaiFycompaNeurologicalNorth AmericaPharmaceuticalRegulation

Eisai gains Swiss approval for Zonegran and Canadian OK for Fycompa

11-07-2013

Japanese drug major Eisai (TYO: 4205) says that Zonegran (zonisamide) has been approved by Switzerland's…

EisaiEuropeFycompaNeurologicalNorth AmericaPharmaceuticalRegulationZonegran

New data provides additional evidence for use of Eisai's Fycompa in partial-onset epilepsy

26-06-2013

Additional data on the safety, efficacy and impact on quality of life (QOL) of Japanese drug major Eisai's…

EisaiFycompaNeurologicalPharmaceuticalResearch

Eisai temporarily suspend Fycompa in Germany, following negative G-BA decision

25-06-2013

Japanese drug major Eisai (TYO: 4523) said today (June 25) that, "with regret," it will suspend temporarily…

EisaiEuropeFycompaMarkets & MarketingNeurologicalPharmaceuticalPricingRegulation

Eisai's Fycompa shows clear therapeutic benefit in hard-to-treat epilepsy

10-05-2013

Japanese drug major Eisai's (TYO: 4523) antiepileptic drug (AED) Fycompa (perampanel), shows a clear…

EisaiFycompaNeurologicalPharmaceuticalResearch

Eisai joins trend to enter Russian pharma market, with Halaven launch

26-03-2013

Japanese drug major Eisai (TYO; 4523, through its EMEA (Europe, Middle East and Africa) unit, has announced…

EisaiEuropeExaliefFycompaHalavenInovelonMarkets & MarketingNeurologicalOncologyPharmaceuticalZonegran

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA

08-03-2013

The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system…

EisaiEuropeFycompaGastro-intestinalsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Eisai expands in South Africa, filing for approval of Halaven and Fycompa

30-01-2013

Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the…

EisaiFycompaHalavenMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationRest of the World

Eisai disagrees with Germany's IQWiG report on epilepsy drug Fycompa

19-12-2012

In the assessment report by the German Institute for Quality and Efficiency in Health Care (IQWiG) on…

EisaiEuropeFycompaNeurologicalPharmaceuticalPricingRegulation

Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME

11-12-2012

Japanese drug major Eisai's (TYO: 4523) Fycompa (perampanel), a treatment for partial epilepsy, is now…

EisaiEuropeFycompaLucentisNeurologicalNovartisPharmaceuticalPricingRegulation

FDA approves Eisai's Fycompa to treat epileptic seizures and Supernus' Oxtellar XR

23-10-2012

The US Food and Drug Administration yesterday approved Japanese drug major Eisai's (TYO: 4523) Fycompa…

EisaiFycompaNeurologicalNorth AmericaOxtellar XRPharmaceuticalRegulationSupernus Pharmaceuticals

Eisai's Fycompa gets first EU launch, in UK; links with Sabine Vaccine Inst

13-09-2012

Japanese drug major Eisai (TYO: 4523) has announced the first European launch today of Fycompa (perampanel),…

EisaiFycompaMarkets & MarketingNeurologicalPharmaceuticalResearchTropical diseasesVaccines

Positive final pivotal Ph III results for Eisai's Fycompa

21-08-2012

Results from the final pivotal Phase III study and long term Phase III extension study of Japanese drug…

EisaiFycompaNeurologicalPharmaceuticalResearch

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco

30-07-2012

Japanese drug major Eisai (TYO: 4523) says that the European Commission has approved for marketing its…

EisaiEuropeFycompaKalydecoNeurologicalPharmaceuticalRare diseasesRegulationVertex

Eisai's Fycompa improves seizure control, pivotal Ph III study shows

27-07-2012

Japanese drug major Eisai (TYO: 4523) announced results from a pivotal Phase III clinical trial (Study…

EisaiFycompaNeurologicalperampanelPharmaceuticalResearch

Zonegran Russian approval prompts Eisai's expansion in that market

28-06-2012

Eisai (TYO: 4523), a leading Japanese drugmaker, says it plans to expand its operations into Russia,…

EisaiEuropeFycompaHalavenMarkets & MarketingNeurologicalPharmaceuticalRegulationZonegran

Back to top